Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osteologix has entered into a definitive agreement with two accredited investors pursuant to which it has agreed to sell, in a private placement, approximately 4.03 million shares of its common stock and warrants to purchase up to 2.02 million shares of common stock.
Subscribe to our email newsletter
Gross proceeds to the company are expected to be approximately $5.3 million. In the purchase agreement, Nordic Biotech Opportunity Fund, an affiliate of Nordic Biotech, the company’s largest shareholder, agreed to purchase approximately 75% of the shares and warrants that will be sold, for gross proceeds of $4 million.
The common stock will be sold for a price of $1.32 per share and the warrants will have an exercise price of $1.32 per share, with an expiration date of September 30, 2009. The company expects the financing to close on or about April 17, 2008, subject to satisfaction of certain customary closing conditions.
The company plans to use the proceeds of the private placement for general corporate purposes including development of its investigational drug NB S101, corporate operating expenses, working capital and capital expenditures.